What is it about?

Alzheimer’s disease (AD) is a complex neurodegenerative disorder, and it is the most prevalent subtype of dementia. We have underlined the vital role of 18F-FDG PET in identifying and staging AD. In addition, we have shown that brain glucose metabolism is associated with cognitive status in AD dementia and vascular risk factors in mild cognitive impairment (MCI) patients, indicating that 18F-FDG PET might be promising for predicting cognitive decline and serve as a visual framework for investigating underlying mechanism of vascular risk factors influencing the conversion from MCI to AD.

Featured Image

Why is it important?

We have underlined the important role of 18F-FDG PET in AD workup, including disease diagnosis, differential diagnosis, staging, and efficacy evaluation. Particularly, we have proposed the associations between brain glucose metabolism and cognitive functions and vascular risk factors in AD dementia, promoting the mechanism investigation how vascular risk factors influence the conversion from MCI to AD.

Perspectives

I hope this article makes what people might think is a boring, slightly abstract area like health economics and measuring things like health, kind of interesting and maybe even exciting. More than anything else, and if nothing else, I hope you find this article thought-provoking.

Sheng-Nan Jiang
The second Affiliated Hospital, Guangzhou Medical University

Read the Original

This page is a summary of: The Association Between Brain Metabolic Biomarkers Using 18F-FDG and Cognition and Vascular Risk Factors, as well as Its Usefulness in the Diagnosis and Staging of Alzheimer’s Disease, Journal of Alzheimer s Disease Reports, September 2024, IOS Press,
DOI: 10.3233/adr-240104.
You can read the full text:

Read

Contributors

The following have contributed to this page